Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
6.020
+0.045 (+0.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine Mindmed Inc
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?
December 30, 2021
Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for inv...
Via
Benzinga
Cannabis Movers & Shakers: MindMed & Trulieve Management Shake-Ups, Credex Corp & CapStone Bolster Leadership Teams
December 29, 2021
MindMed Announces Management Shake-Ups Mind Medicine Inc. (NASDAQ:
Via
Benzinga
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
December 24, 2021
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?
Via
Talk Markets
MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety Disorder
December 22, 2021
MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic...
Via
Benzinga
The Year In Review For Psychedelic Drug Stocks: 2021
December 21, 2021
2021 was two different
Via
Talk Markets
MNMD Stock: The Latest Psychedelic Drug News MindMed Fans Should Watch
December 21, 2021
MindMed's LSD trials are facing a regulatory roadblock but MNMD stock isn't being forced down. Here's why investors should watch.
Via
InvestorPlace
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
December 17, 2021
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.
Via
Talk Markets
MindMed Advances Phase 2a LSD Microdose Trial For Adult ADHD
December 17, 2021
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (...
Via
Benzinga
Mind Medicine to Study Effect of Time on LSD Microdosing
December 17, 2021
Mind Medicine (NASDAQ: MNMD), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a...
Via
Benzinga
Mind Medicine (NASDAQ: MNMD) (NEO: MMED) to Study Effect of Time on LSD Microdosing
December 17, 2021
Via
Investor Brand Network
Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) to Conduct Study Investigating Effect of Time on LSD Microdosing
December 16, 2021
Via
Investor Brand Network
Cannabis Movers & Shakers: HEXO, Agrify, MindMed, KetamineOne
December 15, 2021
Agrify Taps Barry Turkanis To Its Board Of Directors Vertically integrated cannabis company Agrify Corporation (NASDAQ...
Via
Benzinga
MindMed Names Robert Barrow As CEO & Director, Announces Management Shake-Ups
December 14, 2021
Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ:
Via
Benzinga
Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness
December 13, 2021
Photo by Raimond Klavins
Via
Benzinga
Fintech Focus For December 13, 2021
December 12, 2021
One Big Thing In Fintech: Understanding the fundamentals of a publicly-listed company can help with making more informed investment decisions. Still, many fail in conducting any...
Via
Benzinga
North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026
December 14, 2021
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept...
Via
FinancialNewsMedia
EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline
December 10, 2021
This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn. In learning...
Via
Benzinga
BioMedNewsBreaks – Mind Medicine (‘MindMed’) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) Engages with FDA for Development of the ‘MSMS’
December 10, 2021
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
December 09, 2021
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The...
Via
Benzinga
Topics
Derivatives
Exposures
Derivatives
FDA Shows Support For Development Of MindMed's Session Monitoring System
December 09, 2021
Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) recently met with the US Food and Drug Administration (FDA) Center for Devices and...
Via
Benzinga
Exposures
Product Safety
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness
December 08, 2021
Photo by Michael Longmire on...
Via
Benzinga
MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic’ Data
December 01, 2021
MNMD stock is up today after MindMed reported positive findings on the interactions between psilocybin and an antidepressant.
Via
InvestorPlace
Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study Finds
November 30, 2021
Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective...
Via
Benzinga
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
November 23, 2021
Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market....
Via
FinancialNewsMedia
Exposures
COVID-19
Psychedelic Drug Stocks Continued To Decline Last Week
November 21, 2021
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.
Via
Talk Markets
3 Psychedelic Stocks for Potential Out-of-This-World Gains
November 18, 2021
Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress.
Via
InvestorPlace
MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD
November 16, 2021
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results late Monday for the third quarter...
Via
Benzinga
Cannabis Movers & Shakers: Mind Medicine, Avant Brands, Delic, Agrify, Ascend Wellness, Pure Beauty
November 11, 2021
Mind Medicine Appoints Maria A. Oquendo To Scientific Advisory Board Psychedelic-focused biotech company Mind Medicine Inc.
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
November 11, 2021
Compass Pathways reported
Via
Talk Markets
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
November 11, 2021
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.
Via
InvestorPlace
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.